University of Paris Researchers Utilize Fluidigm Mass Cytometry and Maxpar Direct Immune Profiling Assay to Identify Distinct Phenotype among Patients with Severe COVID-19

Stock Information for Fluidigm Corporation

Loading

Please wait while we load your information from QuoteMedia.